# Code STEMI â€“ ST-Elevation Myocardial Infarction with Virtua Voorhees Addenda
## Updated with 2025 ACS Guidelines & UpToDate Evidence

**Primary Guideline:** 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for Management of Patients with Acute Coronary Syndromes
**Official Source:** https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309
**Supporting Guidelines:** 
- 2021 ACC/AHA/SCAI Coronary Revascularization Guidelines
- UpToDate STEMI Management Review 2025

## ENHANCED MERMAID FLOWCHART ALGORITHM

~~~mermaid
graph TD
    A["Chest Pain/ACS Symptoms<br/>Obtain 12-lead ECG â‰¤10min"] --> B{"STEMI Criteria<br/>Met?"}
    
    B -->|YES| C["Rule out STEMI Mimics<br/>Activate Code STEMI<br/>ASA + IV Access + Labs"]
    B -->|NO| D["Evaluate STEMI Equivalents<br/>NSTEACS Assessment"]
    
    C --> E["Assess Life-threatening<br/>Conditions"]
    D --> F{"Risk Level<br/>Assessment?"}
    
    E --> G{"Primary PCI Available<br/>within 120min?"}
    
    F -->|HIGH RISK| H["Urgent Catheterization<br/>within 24h"]
    F -->|LOW-INTERMEDIATE| I["Conservative/Selective<br/>Management"]
    
    G -->|YES| J["Primary PCI Preparation<br/>DAPT + UFH"]
    G -->|NO| K["Fibrinolytic Screening<br/>Contraindications Check"]
    
    J --> L["Cath Lab Procedure<br/>Door-to-Balloon <90min"]
    
    K --> M{"Fibrinolytic<br/>Contraindications?"}
    M -->|NO| N["TNK Administration<br/>0.25mg/kg bolus"]
    M -->|YES| O["Transfer for Rescue PCI<br/>Call 856-886-5111"]
    
    L --> P["Monitor Reperfusion<br/>ST Resolution Assessment"]
    N --> P
    O --> P
    H --> P
    I --> P
    
    P --> Q{"Reperfusion<br/>Success?"}
    
    Q -->|SUCCESS| R["Post-STEMI Care<br/>GDMT + Discharge Planning"]
    Q -->|FAILED| S["Rescue Intervention<br/>Emergency PCI"]
    Q -->|SHOCK| T["MCS Consideration<br/>IABP/Impella/ECMO"]
    
    style A fill:#ffcccc
    style C fill:#ffe6cc
    style J fill:#fff2cc
    style L fill:#ccffcc
    style N fill:#e6ccff
    style R fill:#ccffee
~~~

## STREAMLINED DYNAMIC CARD SYSTEM - 2025 UPDATED

### Card 0 â€“ Initial Assessment & ECG (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ«€ ACUTE CHEST PAIN ASSESSMENT          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â±ï¸ CRITICAL TIMING:                     â”‚
â”‚ â€¢ 12-lead ECG within 10 minutes        â”‚
â”‚ â€¢ Repeat q15-30min if initial non-diagnosticâ”‚
â”‚                                         â”‚
â”‚ ğŸ“Š STEMI CRITERIA (2025 Updated):       â”‚
â”‚ â€¢ â‰¥1mm ST elevation, â‰¥2 contiguous leadsâ”‚
â”‚ â€¢ V2-V3 criteria (age/sex specific):   â”‚
â”‚   - Males â‰¥40y: â‰¥2mm                   â”‚
â”‚   - Males <40y: â‰¥2.5mm                 â”‚
â”‚   - Females: â‰¥1.5mm                    â”‚
â”‚ â€¢ New LBBB with clinical correlation   â”‚
â”‚                                         â”‚
â”‚ â“ STEMI criteria met?                  â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Rule out mimics & activate    â”‚
â”‚ ğŸ”˜ NO â†’ STEMI equivalents assessment   â”‚
â”‚                                         â”‚
â”‚ [Next: Based on Selection â–¶]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1A â€“ STEMI Activation & Mimic Assessment (Node C â†’ E)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ CODE STEMI ACTIVATION                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš€ Immediate actions (<10 minutes):     â”‚
â”‚ â€¢ ASA 162-325mg chewed                 â”‚
â”‚ â€¢ IV access Ã— 2 (18G)                  â”‚
â”‚ â€¢ Labs: CBC, BMP, PT/INR, troponin     â”‚
â”‚ â€¢ Call 856-886-5111 (Transfer Center)  â”‚
â”‚                                         â”‚
â”‚ âš ï¸ STEMI mimics to exclude:             â”‚
â”‚ â€¢ Pericarditis (diffuse, PR depression)â”‚
â”‚ â€¢ Early repolarization (young, athletic)â”‚
â”‚ â€¢ LVH with strain pattern              â”‚
â”‚ â€¢ Takotsubo cardiomyopathy             â”‚
â”‚                                         â”‚
â”‚ [Next: Life-threatening assessment â–¶]   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Initial Assessment]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1B â€“ STEMI Equivalents & NSTEACS (Node D â†’ F)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ” STEMI EQUIVALENTS & NSTEACS          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ High-risk equivalent patterns:       â”‚
â”‚ â€¢ De Winter sign (ST depression + hyperacute T)â”‚
â”‚ â€¢ Posterior STEMI (ST depression V1-V3)â”‚
â”‚ â€¢ Wellens sign (biphasic T waves V2-V3)â”‚
â”‚ â€¢ Hyperacute T waves                   â”‚
â”‚ â€¢ New LBBB with Sgarbossa criteria     â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š NSTEACS features:                    â”‚
â”‚ â€¢ ST depression â‰¥0.5mm (â‰¥2 contiguous) â”‚
â”‚ â€¢ T wave inversion â‰¥1mm with R wave    â”‚
â”‚ â€¢ Positive cardiac biomarkers          â”‚
â”‚                                         â”‚
â”‚ [Next: Risk stratification â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Initial Assessment]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ Life-Threatening Assessment (Node E â†’ G)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš ï¸ LIFE-THREATENING CONDITIONS          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ” Evaluate immediately:                â”‚
â”‚ â€¢ Cardiogenic shock (cool extremities, â”‚
â”‚   JVD, hypotension)                    â”‚
â”‚ â€¢ Acute heart failure (orthopnea,      â”‚
â”‚   pulmonary edema)                     â”‚
â”‚ â€¢ Aortic dissection (tearing pain,     â”‚
â”‚   pulse deficits, new murmur)          â”‚
â”‚ â€¢ Ventricular arrhythmias              â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Contraindications assessment:        â”‚
â”‚ â€¢ Bleeding risk, anticoagulant use     â”‚
â”‚ â€¢ Recent surgery, trauma              â”‚
â”‚ â€¢ Coagulopathy, thrombocytopenia       â”‚
â”‚                                         â”‚
â”‚ [Next: PCI availability decision â–¶]    â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: STEMI Activation]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2B â€“ Risk Stratification (Node F)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š NSTEACS RISK ASSESSMENT              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš¨ High-risk features:                  â”‚
â”‚ â€¢ Recurrent ischemic symptoms          â”‚
â”‚ â€¢ Dynamic ECG changes                  â”‚
â”‚ â€¢ Hemodynamic instability              â”‚
â”‚ â€¢ Sustained VT/VF                      â”‚
â”‚ â€¢ Elevated troponin levels             â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Risk scores (use clinical judgment): â”‚
â”‚ â€¢ GRACE score for 6-month risk         â”‚
â”‚ â€¢ TIMI risk score for events           â”‚
â”‚                                         â”‚
â”‚ â“ Risk level determined?               â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ HIGH â†’ Urgent cath within 24h       â”‚
â”‚ ğŸ”˜ LOW-INTERMEDIATE â†’ Conservative mgmt â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ PCI Availability Decision (Node G)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â±ï¸ PRIMARY PCI AVAILABILITY             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Time-critical decision points:       â”‚
â”‚ â€¢ Door-to-balloon <90min (on-site PCI) â”‚
â”‚ â€¢ First medical contact to device       â”‚
â”‚   <120min (transfer required)          â”‚
â”‚ â€¢ Consider patient factors: age, comorbiditiesâ”‚
â”‚                                         â”‚
â”‚ ğŸ“ Transfer coordination:               â”‚
â”‚ â€¢ Call 856-886-5111 immediately        â”‚
â”‚ â€¢ Direct communication with PCI center â”‚
â”‚ â€¢ Expedited transport arrangements     â”‚
â”‚                                         â”‚
â”‚ â“ Primary PCI achievable <120min?      â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Primary PCI preparation       â”‚
â”‚ ğŸ”˜ NO â†’ Fibrinolytic evaluation        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Primary PCI Preparation (Node J â†’ L)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ PRIMARY PCI PREPARATION              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Dual antiplatelet therapy:           â”‚
â”‚ â€¢ Ticagrelor 180mg load (preferred)    â”‚
â”‚ â€¢ Prasugrel 60mg load (avoid if:       â”‚
â”‚   age â‰¥75y, <60kg, stroke history)     â”‚
â”‚ â€¢ Clopidogrel 600mg load (high bleed risk)â”‚
â”‚                                         â”‚
â”‚ ğŸ©¸ Anticoagulation:                     â”‚
â”‚ â€¢ UFH 70-100 units/kg bolus            â”‚
â”‚   (max 10,000 units, no GP IIb/IIIa)  â”‚
â”‚ â€¢ UFH 50-70 units/kg bolus             â”‚
â”‚   (max 7,000 units, with GP IIb/IIIa)  â”‚
â”‚ â€¢ Bivalirudin if HIT history            â”‚
â”‚                                         â”‚
â”‚ [Next: Cath lab procedure â–¶]           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: PCI Availability]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4B â€“ Fibrinolytic Screening (Node K â†’ M)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’‰ FIBRINOLYTIC THERAPY SCREENING       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… Inclusion criteria:                  â”‚
â”‚ â€¢ Symptom onset <12 hours              â”‚
â”‚ â€¢ STEMI with no access to PCI <120min  â”‚
â”‚ â€¢ Age â‰¥18 years                        â”‚
â”‚                                         â”‚
â”‚ ğŸš« Major contraindications:             â”‚
â”‚ â€¢ History of intracranial hemorrhage   â”‚
â”‚ â€¢ Ischemic stroke <3 months            â”‚
â”‚ â€¢ Active bleeding or bleeding disorder â”‚
â”‚ â€¢ Aortic dissection suspected          â”‚
â”‚ â€¢ Significant trauma <3 months         â”‚
â”‚                                         â”‚
â”‚ [Next: Contraindication assessment â–¶]   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: PCI Availability]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Urgent Catheterization (Node H - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ URGENT CATHETERIZATION <24H          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ High-risk NSTEACS management:        â”‚
â”‚ â€¢ Early invasive strategy indicated    â”‚
â”‚ â€¢ DAPT + anticoagulation optimization  â”‚
â”‚ â€¢ Hemodynamic monitoring               â”‚
â”‚ â€¢ Prepare for possible PCI             â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Medical therapy during wait:         â”‚
â”‚ â€¢ Continue dual antiplatelet therapy   â”‚
â”‚ â€¢ UFH or enoxaparin anticoagulation    â”‚
â”‚ â€¢ Beta blocker if no contraindications â”‚
â”‚                                         â”‚
â”‚ âœ… URGENT CATHETERIZATION PROTOCOL ACTIVEâ”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Risk Stratification]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5B â€“ Conservative Management (Node I - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ›¡ï¸ CONSERVATIVE MANAGEMENT              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Medical therapy optimization:        â”‚
â”‚ â€¢ Dual antiplatelet: ASA + P2Y12       â”‚
â”‚ â€¢ Anticoagulation: UFH, enoxaparin,    â”‚
â”‚   or fondaparinux                      â”‚
â”‚ â€¢ Beta blocker (if no contraindications)â”‚
â”‚ â€¢ High-intensity statin                â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring strategy:                 â”‚
â”‚ â€¢ Serial cardiac biomarkers           â”‚
â”‚ â€¢ Continuous telemetry monitoring      â”‚
â”‚ â€¢ Consider selective angiography       â”‚
â”‚   if symptoms recur                    â”‚
â”‚                                         â”‚
â”‚ âœ… CONSERVATIVE PROTOCOL ACTIVE        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Risk Stratification]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6A â€“ Cath Lab Procedure (Node L â†’ P)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ CARDIAC CATHETERIZATION              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Procedure goals:                     â”‚
â”‚ â€¢ Identify culprit vessel              â”‚
â”‚ â€¢ Achieve TIMI 3 flow                 â”‚
â”‚ â€¢ Address culprit lesion first         â”‚
â”‚ â€¢ Consider multivessel intervention    â”‚
â”‚   if cardiogenic shock                 â”‚
â”‚                                         â”‚
â”‚ â±ï¸ Time targets:                        â”‚
â”‚ â€¢ Door-to-balloon <90 minutes          â”‚
â”‚ â€¢ Minimize procedural delays           â”‚
â”‚                                         â”‚
â”‚ ğŸ”§ Consider mechanical support:         â”‚
â”‚ â€¢ IABP for cardiogenic shock           â”‚
â”‚ â€¢ Impella for severe LV dysfunction    â”‚
â”‚                                         â”‚
â”‚ [Next: Reperfusion monitoring â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: PCI Preparation]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6B â€“ Contraindication Assessment (Node M)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ” FIBRINOLYTIC CONTRAINDICATIONS       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“‹ Systematic evaluation:               â”‚
â”‚ â€¢ Complete bleeding history            â”‚
â”‚ â€¢ Recent procedures/surgeries          â”‚
â”‚ â€¢ Current medications (anticoagulants) â”‚
â”‚ â€¢ Age considerations (>75y relative CI)â”‚
â”‚                                         â”‚
â”‚ âš–ï¸ Risk-benefit analysis:               â”‚
â”‚ â€¢ Severity of STEMI presentation       â”‚
â”‚ â€¢ Time from symptom onset             â”‚
â”‚ â€¢ Availability of alternative therapy  â”‚
â”‚                                         â”‚
â”‚ â“ Contraindications present?           â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ NO â†’ Administer TNK                â”‚
â”‚ ğŸ”˜ YES â†’ Rescue PCI transfer          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7A â€“ TNK Administration (Node N â†’ P)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’‰ TENECTEPLASE ADMINISTRATION          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š TNK protocol (weight-based):         â”‚
â”‚ â€¢ Dose: 0.25mg/kg IV bolus (max 25mg)  â”‚
â”‚ â€¢ Single push over 5 seconds           â”‚
â”‚ â€¢ Dedicated IV line, flush after       â”‚
â”‚                                         â”‚
â”‚ ğŸ©¸ Adjunctive therapy:                  â”‚
â”‚ â€¢ UFH: 60 units/kg bolus               â”‚
â”‚   â†’ 12 units/kg/hr infusion            â”‚
â”‚ â€¢ Clopidogrel 300mg if age <75y        â”‚
â”‚   75mg if age â‰¥75y                     â”‚
â”‚                                         â”‚
â”‚ ğŸš« Avoid for 24 hours:                 â”‚
â”‚ â€¢ Additional anticoagulants/antiplateletsâ”‚
â”‚ â€¢ Arterial punctures                   â”‚
â”‚                                         â”‚
â”‚ [Next: Reperfusion monitoring â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Contraindication Check]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7B â€“ Rescue PCI Transfer (Node O â†’ P)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš RESCUE PCI TRANSFER                 â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ Immediate coordination:              â”‚
â”‚ â€¢ Call 856-886-5111 (Transfer Center)  â”‚
â”‚ â€¢ Direct communication with PCI center â”‚
â”‚ â€¢ Expedited transport (air if >30min)  â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Continue medical therapy:            â”‚
â”‚ â€¢ Maintain antiplatelet therapy        â”‚
â”‚ â€¢ UFH anticoagulation                  â”‚
â”‚ â€¢ Supportive care during transport     â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Target: Emergency PCI capability     â”‚
â”‚                                         â”‚
â”‚ [Next: Reperfusion monitoring â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Contraindication Check]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8 â€“ Reperfusion Monitoring (Node P â†’ Q)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ˆ REPERFUSION SUCCESS MONITORING       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Success indicators (assess at 90min): â”‚
â”‚ â€¢ ST segment resolution >50%           â”‚
â”‚ â€¢ Complete resolution of chest pain    â”‚
â”‚ â€¢ Hemodynamic stability               â”‚
â”‚ â€¢ No new arrhythmias                  â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Failure indicators:                  â”‚
â”‚ â€¢ <30% ST resolution at 90 minutes     â”‚
â”‚ â€¢ Persistent/worsening chest pain      â”‚
â”‚ â€¢ Hemodynamic deterioration           â”‚
â”‚ â€¢ New mechanical complications         â”‚
â”‚                                         â”‚
â”‚ ğŸ” Additional monitoring:               â”‚
â”‚ â€¢ Continuous telemetry                â”‚
â”‚ â€¢ Serial 12-lead ECGs                 â”‚
â”‚ â€¢ Cardiac biomarker trending          â”‚
â”‚                                         â”‚
â”‚ â“ Reperfusion successful?              â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ SUCCESS â†’ Post-STEMI care          â”‚
â”‚ ğŸ”˜ FAILED â†’ Rescue intervention       â”‚
â”‚ ğŸ”˜ SHOCK â†’ MCS consideration          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9A â€“ Post-STEMI Care (Node R - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ POST-STEMI OPTIMIZATION              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Guideline-directed medical therapy:  â”‚
â”‚ â€¢ DAPT: ASA + P2Y12 inhibitor          â”‚
â”‚ â€¢ Beta blocker (unless contraindicated)â”‚
â”‚ â€¢ ACE inhibitor or ARB                 â”‚
â”‚ â€¢ High-intensity statin (atorvastatin 80mg)â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring & assessment:             â”‚
â”‚ â€¢ Echocardiogram for EF assessment     â”‚
â”‚ â€¢ Lipid panel, HbA1c if diabetic      â”‚
â”‚ â€¢ Assessment for mechanical complicationsâ”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Discharge planning:                  â”‚
â”‚ â€¢ Cardiac rehabilitation referral      â”‚
â”‚ â€¢ Follow-up appointments (1-2 weeks)   â”‚
â”‚ â€¢ Patient education and lifestyle mods â”‚
â”‚                                         â”‚
â”‚ âœ… POST-STEMI PROTOCOL COMPLETE        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Success Monitoring]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9B â€“ Rescue Intervention (Node S - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ RESCUE INTERVENTION                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âš ï¸ Failed reperfusion management:       â”‚
â”‚ â€¢ Emergency cardiac catheterization    â”‚
â”‚ â€¢ Consider rescue PCI if post-fibrinolyticâ”‚
â”‚ â€¢ Mechanical thrombectomy if indicated â”‚
â”‚ â€¢ Address complications aggressively   â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ Intensive monitoring:                â”‚
â”‚ â€¢ ICU-level care                       â”‚
â”‚ â€¢ Hemodynamic monitoring               â”‚
â”‚ â€¢ Serial ECGs and biomarkers           â”‚
â”‚                                         â”‚
â”‚ ğŸ“ Multidisciplinary team approach:     â”‚
â”‚ â€¢ Interventional cardiology           â”‚
â”‚ â€¢ Critical care medicine              â”‚
â”‚ â€¢ Cardiac surgery if needed           â”‚
â”‚                                         â”‚
â”‚ âœ… RESCUE PROTOCOL ACTIVE              â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Success Monitoring]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9C â€“ Mechanical Circulatory Support (Node T - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’“ MECHANICAL CIRCULATORY SUPPORT       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš¨ Cardiogenic shock indications:       â”‚
â”‚ â€¢ SBP <90 mmHg despite volume          â”‚
â”‚ â€¢ Cardiac index <2.2 L/min/mÂ²         â”‚
â”‚ â€¢ Pulmonary capillary wedge >18 mmHg   â”‚
â”‚ â€¢ End-organ hypoperfusion              â”‚
â”‚                                         â”‚
â”‚ ğŸ›¡ï¸ MCS device options:                  â”‚
â”‚ â€¢ IABP: First-line for most patients   â”‚
â”‚ â€¢ Impella CP/5.0: Severe LV failure    â”‚
â”‚ â€¢ VA-ECMO: Refractory cardiogenic shock â”‚
â”‚ â€¢ Consider heart team consultation     â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring requirements:             â”‚
â”‚ â€¢ Invasive hemodynamic monitoring      â”‚
â”‚ â€¢ Frequent assessment of organ functionâ”‚
â”‚ â€¢ Anticoagulation management          â”‚
â”‚                                         â”‚
â”‚ âœ… MCS PROTOCOL ACTIVE                 â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Success Monitoring]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES ENHANCED PROTOCOL ADDENDA

### **2025 Guideline Updates Integrated:**
- **Updated STEMI Criteria:** Age and sex-specific thresholds for V2-V3 leads
- **Time-Critical Metrics:** ECG within 10 minutes, door-to-balloon <90 minutes
- **Enhanced Risk Assessment:** Systematic evaluation for life-threatening conditions
- **Antiplatelet Optimization:** Ticagrelor preferred, prasugrel with specific exclusions
- **Transfer Protocols:** 120-minute first medical contact to device time

### **Critical Contact Information:**
- **STEMI Transfer Center:** 856-886-5111 (24/7 immediate response)
- **Emergency Activation:** Direct cath lab hot line
- **Air Medical Transport:** Weather permitting, >30-minute ground transport time

### **Enhanced Quality Metrics:**
- **Door-to-ECG:** <10 minutes (target: 5 minutes)
- **Door-to-Balloon (Primary PCI):** <90 minutes (target: 60 minutes)
- **First Medical Contact to Device:** <120 minutes (transfer cases)
- **Reperfusion Success Rate:** >95% TIMI 3 flow achievement

### **Medication Protocols - Evidence Based:**
**Immediate Actions:**
- **Aspirin:** 162-325mg chewed (unless anaphylaxis/aortic dissection)
- **Beta Blockers:** Oral within 24 hours (avoid if shock/heart failure)
- **Statins:** High-intensity (atorvastatin 80mg) within 24 hours

**Advanced Therapies:**
- **P2Y12 Inhibitor Selection:** Based on bleeding risk, age, weight
- **Anticoagulation:** UFH preferred for PCI, consider bivalirudin if HIT
- **Fibrinolytic Choice:** TNK preferred over alteplase (single bolus)

### **Special Population Considerations:**
- **COVID-19 Patients:** Standard STEMI care with appropriate PPE
- **Pregnancy:** Avoid fibrinolytics, prefer PCI with radiation protection
- **Elderly (â‰¥75y):** Careful bleeding risk assessment, prefer clopidogrel
- **Cardiogenic Shock:** Immediate PCI regardless of symptom duration

### **System Integration Features:**
- **Real-time Decision Support:** Automated contraindication checking
- **Quality Dashboard:** Live D2B time monitoring and alerts
- **Mobile Alerts:** Push notifications for time-critical milestones
- **Documentation:** Automated protocol adherence tracking

### **Complications Management:**
- **Mechanical Complications:** Emergency surgical consultation
- **No-Reflow Phenomenon:** Intracoronary vasodilators, thrombectomy
- **Contrast-Induced Nephropathy:** Pre-hydration, minimize contrast volume
- **Bleeding Complications:** Rapid reversal protocols available

## REFERENCE GUIDELINES & EVIDENCE BASE
- **2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS Guidelines**
- **2021 ACC/AHA/SCAI Coronary Revascularization Guidelines** 
- **UpToDate STEMI Management Review - Updated April 2025**
- **Virtua Health System STEMI Protocol v2025**

**This comprehensive protocol reflects the latest evidence-based approach to STEMI management, optimized for rapid recognition, appropriate reperfusion strategy selection, and excellent patient outcomes at Virtua Voorhees.**
